Literature DB >> 20487614

First national survey of Mycobacterium tuberculosis drug resistance, Madagascar, 2005-2006.

H Ramarokoto1, O Ratsirahonana, J L Soares, J Ravaosolo, P Ravololonandriana, A Rakotoarisaonina, G Ranjalahy, S Ranaivohajaina, M Mosa, R Robinson, M Ratsitorahina, V Rasolofo, B Rarivoson.   

Abstract

SETTING: A national survey of Mycobacterium tuberculosis resistance was conducted for the first time in Madagascar between October 2005 and July 2007.
OBJECTIVE: To determine resistance rates among new and previously treated cases of pulmonary tuberculosis.
METHODS: In a cluster sampling representative of the general population of the country, 1275 smear-positive tuberculosis patients recruited at 34 sites, 926 new patients and 87 previously treated patients underwent drug susceptibility testing against rifampicin (RMP), isoniazid (INH), streptomycin and ethambutol on Löwenstein-Jensen medium using the indirect proportion method.
RESULTS: Resistance among new cases was 6.5% (95%CI 4.9-8) and among previously treated cases it was 11.5% (95%CI 4.8-18.2). Monoresistance among new cases was 5.8% (95%CI 4.2-7.3), mainly to INH (3.7%). Multiresistance to INH and RMP was 0.2% (95%CI 0-0.5) among new cases and 3.4% (95%CI 0-7.2) among previously treated cases. No significant difference was noted with regard to sex or age.
CONCLUSION: The rates of resistance among new and previously treated cases remain relatively low in Madagascar.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20487614

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

Review 1.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.

Authors:  Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen
Journal:  Lancet       Date:  2014-03-24       Impact factor: 79.321

Review 2.  Isoniazid-resistant tuberculosis in children: a systematic review.

Authors:  Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

Review 3.  Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Deus Lukoye; Willy Ssengooba; Kenneth Musisi; George W Kasule; Frank G J Cobelens; Moses Joloba; Gabriela B Gomez
Journal:  BMC Public Health       Date:  2015-03-25       Impact factor: 3.295

4.  Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010.

Authors:  Renata Báez-Saldaña; Guadalupe Delgado-Sánchez; Lourdes García-García; Luis Pablo Cruz-Hervert; Marlene Montesinos-Castillo; Leticia Ferreyra-Reyes; Miriam Bobadilla-Del-Valle; Sergio Canizales-Quintero; Elizabeth Ferreira-Guerrero; Norma Téllez-Vázquez; Rogelio Montero-Campos; Mercedes Yanes-Lane; Norma Mongua-Rodriguez; Rosa Areli Martínez-Gamboa; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

Review 5.  Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis.

Authors:  Baba Maiyaki Musa; Aishatu L Adamu; Najibah A Galadanci; Bashir Zubayr; Chisom N Odoh; Muktar H Aliyu
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

6.  Multidrug-resistant tuberculosis surveillance and cascade of care in Madagascar: a five-year (2012-2017) retrospective study.

Authors:  Astrid M Knoblauch; Simon Grandjean Lapierre; Daniella Randriamanana; Mamy Serge Raherison; Andrianantenaina Rakotoson; Bienvenue Solofomandimby Raholijaona; Masiarivony Ravaoarimanga; Pascaline Elisabeth Ravololonandriana; Marie-Sylvianne Rabodoarivelo; Orelys Ratsirahonana; Fanjasoa Rakotomanana; Turibio Razafindranaivo; Voahangy Rasolofo; Niaina Rakotosamimanana
Journal:  BMC Med       Date:  2020-06-30       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.